Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Pitzer, Virginia E ^a,b   Bilcke, Joke ^c   Heylen, Elisabeth ^d   Crawford, Forrest W ^a   Callens, Michael ^e   De Smet, Frank ^e,f   Van Ranst, Marc ^d   Zeller, Mark ^d   Matthijnssens, Jelle ^d  

^a YALE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e National Alliance of Christian Sickness Funds   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

BELGIUM; GENOTYPE; HUMAN; PATHOGENICITY; ROTAVIRUS; ROTAVIRUS INFECTIONS; THEORETICAL MODEL; VACCINATION; VIROLOGY;

BELGIUM; GENOTYPE; HUMANS; MODELS, THEORETICAL; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 84951304770     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18585     Document Type: Article

References (61)

1. Tate, J. E. et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 136-141 (2012).
2. SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol. Rec. 84, 220-236 (2009).
3. Tate, J. E. & Parashar, U. D. Rotavirus vaccines in routine use. Clin. Infect. Dis. 59, 1291-1301 (2014).
4. Estes, M. & Kapikian, A. In Fields Virology, Fifth edition (eds D. M. Knipe et al.) Ch. 53, 1917-1974 (Kluwer Health/Lippincott, Williams and Wilkins, 2007).
5. Tate, J. E. et al. Trends in national rotavirus activity before and after introduction of rotavirus vaccine into the national immunization program in the United States, 2000 to 2012. Pediatr. Infect. Dis. J. 32, 741-744 (2013).
6. Matthijnssens, J. & Van Ranst, M. Genotype constellation and evolution of group A rotaviruses infecting humans. Curr. Opin. Virol. 2, 426-433 (2012).
7. Matthijnssens, J. et al. Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Arch. Virol. 153, 1621-1629 (2008).
8. Trojnar, E. et al. Identification of an avian group A rotavirus containing a novel VP4 gene with a close relationship to those of mammalian rotaviruses. J. Gen. Virol. 94, 136-142 (2013).
9. Matthijnssens, J. et al. G8 rotavirus strains isolated in the Democratic Republic of Congo belong to the DS-1-like genogroup. J. Clin. Microbiol. 44, 1801-1809 (2006).
10. McDonald, S. M. et al. Evolutionary dynamics of human rotaviruses: balancing reassortment with preferred genome constellations. PLoS Pathog. 5, e1000634 (2009).
11. Heylen, E. et al. Rotavirus surveillance in Kisangani, the Democratic Republic of the Congo, reveals a high number of unusual genotypes and gene segments of animal origin in non-vaccinated symptomatic children. PLoS ONE. 9, e100953 (2014).
12. Wang, Y. H. et al. Molecular epidemiology and genetic evolution of the whole genome of G3P[8] human rotavirus in Wuhan, China, from 2000 through 2013. PLoS ONE. 9, e88850 (2014).
13. Ianiro, G. et al. Genetic diversity of G9P[8] rotavirus strains circulating in Italy in 2007 and 2010 as determined by whole genome sequencing. Infect. Genet. Evol. 16, 426-432 (2013).
14. Gomez, M. M. et al. Phylogenetic analysis of G1P[6] group A rotavirus strains detected in Northeast Brazilian children fully vaccinated with Rotarix. Infect. Genet. Evol. 19, 395-402 (2013).
15. Heylen, E. et al. Complete genetic characterization of human G2P[6] and G3P[6] rotavirus strains. Infect. Genet. Evol. 13, 27-35 (2013).
16. McDonald, S. M., Davis, K., McAllen, J. K., Spiro, D. J. & Patton, J. T. Intra-genotypic diversity of archival G4P[8] human rotaviruses from Washington, DC. Infect. Genet. Evol. 11, 1586-1594 (2011).
17. Rahman, M. et al. Evolutionary history and global spread of the emerging G12 human rotaviruses. J. Virol. 81, 2382-2390 (2007).
18. Gomez, M. M. et al. Distinct evolutionary origins of G12P[8] and G12P[9] group A rotavirus strains circulating in Brazil. Infect. Genet. Evol. 28, 385-388 (2014).
19. Banyai, K. et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine 30 Suppl 1, A122-130 (2012).
20. Matthijnssens, J. et al. Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes? Expert Rev. Vaccines. 11, 1347-1354 (2012).
21. Ward, R. Mechanisms of protection against rotavirus infection and disease. Pediatr. Infect. Dis. J. 28, S57-59 (2009).
22. Matthijnssens, J. et al. Molecular and biological characterization of the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq(R). Virology. 403, 111-127 (2010).
23. Jain, S., Vashistt, J. & Changotra, H. Rotaviruses: is their surveillance needed? Vaccine. 32, 3367-3378 (2014).
24. Hull, J. J. et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr. Infect. Dis. J. 30, S42-47 (2011).
25. Kirkwood, C. D., Boniface, K., Barnes, G. L. & Bishop, R. F. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. Pediatr. Infect. Dis. J. 30, S48-53 (2011).
26. Kirkwood, C. D., Roczo-Farkas, S. & Australian Rotavirus Surveillance, G. Australian Rotavirus Surveillance Program annual report, 2013. Commun. Dis. Intell. Q. Rep. 38, E334-342 (2014).
27. Carvalho-Costa, F. A. et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr. Infect. Dis. J. 30, S35-41 (2011).
28. Zeller, M. et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine. 28, 7507-7513 (2010).
29. Braeckman, T. et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ. 345, e4752 (2012).
30. Matthijnssens, J. et al. Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. Clin. Microbiol. Infect. 20, O702-710 (2014).
31. Pitzer, V. E. et al. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc. Natl Acad. Sci. USA 108, 19353-19358 (2011).
32. Weidemann, F., Dehnert, M., Koch, J., Wichmann, O. & Hohle, M. Modelling the epidemiological impact of rotavirus vaccination in Germany-a Bayesian approach. Vaccine. 32, 5250-5257 (2014).
33. Sabbe, M. et al. Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium. Eurosurveillance (in press).
34. Bilcke, J. et al. Quantifying Parameter and Structural Uncertainty of Dynamic Disease Transmission Models Using MCMC: An Application to Rotavirus Vaccination in England and Wales. Med. Decis. Making. 35, 633-647 (2015).
35. Hahne, S. et al. Exceptionally low rotavirus incidence in the Netherlands in 2013/14 in the absence of rotavirus vaccination. Euro Surveill. 19, pii: 20945 (2014).
36. Zeller, M. et al. Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq. J. Clin. Microbiol. 50, 966-976 (2012).
37. Hungerford, D. & Iturriza-Gomara, M. EuroRotaNet: Annual Report 2014. (2014) Available at: http://www.eurorota.net/(Accessed: 17 September 2015).
38. Dóró, R. et al. Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: Is there evidence of strain selection from vaccine pressure? Infect. Genet. Evol. 28, 446-461 (2014).
39. Gurgel, R. Q. et al. Incidence of rotavirus and circulating genotypes in Northeast Brazil during 7 years of national rotavirus vaccination. PLoS ONE. 9, e110217 (2014).
40. Matthijnssens, J. et al. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol. 4, 1303-1316 (2009).
41. Pitzer, V. E. et al. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PLoS ONE. 7, e42320 (2012).
42. Matthijnssens, J. et al. Phylodynamic analyses of rotavirus genotypes G9 and G12 underscore their potential for swift global spread. Mol. Biol. Evol. 27, 2431-2436 (2010).
43. Pitzer, V. E. et al. Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. J. R. Soc. Interface. 8, 1584-1593 (2011).
44. Pitzer, V. E. et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science. 325, 290-294 (2009).
45. Velasquez, D. E., Parashar, U. D. & Jiang, B. Strain diversity plays no major role in the varying efficacy of rotavirus vaccines: an overview. Infect. Genet. Evol. 28, 561-571 (2014).
46. Steele, A. D. et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect. Dis. 12, 213 (2012).
47. Leshem, E. et al. Rotavirus vaccines and health care utilization for diarrhea in the United States (2007-2011). Pediatrics. 134, 15-23 (2014).
48. Groome, M. J. et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect. Dis. 14, 1096-1104 (2014).
49. Rahman, M. et al. Predominance of rotavirus G9 genotype in children hospitalized for rotavirus gastroenteritis in Belgium during 1999-2003. J. Clin. Virol. 33, 1-6 (2005).
50. van der Donck, I. et al. [Severe diarrhea due to rotavirus infection in a Belgian hospital 1981-2002]. Acta Clin. Belg. 58, 12-18 (2003).
51. Linhares, A. C. et al. Longitudinal study of rotavirus infections among children from Belem, Brazil. Epidemiol. Infect. 102, 129-145 (1989).
52. White, L. J., Waris, M., Cane, P. A., Nokes, D. J. & Medley, G. F. The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection. Epidemiol. Infect. 133, 279-289 (2005).
53. Wilde, J., Yolken, R., Willoughby, R. & Eiden, J. Improved detection of rotavirus shedding by polymerase chain reaction. Lancet. 337, 323-326 (1991).
54. Velazquez, F. R. et al. Rotavirus infections in infants as protection against subsequent infections. N. Engl. J. Med. 335, 1022-1028 (1996).
55. Kang, G. et al. Quantitation of group A rotavirus by real-time reverse-transcription-polymerase chain reaction: correlation with clinical severity in children in South India. J. Med. Virol. 73, 118-122 (2004).
56. Koopman, J. S., Monto, A. S. & Longini, I. M. Jr. The Tecumseh Study. XVI: Family and community sources of rotavirus infection. Am. J. Epidemiol. 130, 760-768 (1989).
57. Ward, R. L. et al. Protection of adults rechallenged with a human rotavirus. J. Infect. Dis. 161, 440-445 (1990).
58. Ward, R. L. et al. Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J. Infect. Dis. 154, 871-880 (1986).
59. Mukhopadhya, I. et al. Rotavirus shedding in symptomatic and asymptomatic children using reverse transcription-quantitative PCR. J. Med. Virol. 85, 1661-1668 (2013).
60. Chiba, S., Nakata, S., Ukae, S. & Adachi, N. Virological and serological aspects of immune resistance to rotavirus gastroenteritis. Clin. Infect. Dis. 16 Suppl 2, S117-121 (1993).
61. Patel, M. et al. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J. Infect. Dis. 208, 284-294 (2013).